Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 74
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03532217 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | ||
| NCT03358563 | Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | ||
| NCT04447703 | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study | ||
| NCT03761160 | Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy | ||
| NCT02080650 | Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) | ||
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | ||
| NCT03276572 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | ||
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | ||
| NCT02582697 | Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours | ||
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | ||
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | ||
| NCT03492424 | Ablative Therapy in the Management of Prostate Cancer | ||
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ||
| NCT04090528 | pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | ||
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | ||
| NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | ||
| NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | ||
| NCT06171139 | Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer | ||
| NCT02735252 | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | ||
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome | ||
| NCT07002320 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer | ||
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | ||
| NCT05041504 | A Web-based Peer Navigation Program for Men With Prostate Cancer | ||
| NCT00651222 | Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy | ||
| NCT02677376 | Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC | ||
| NCT04116775 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | ||
| NCT02478125 | Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer | ||
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | ||
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | ||
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | ||
| NCT05435495 | Mechanisms of Resistance to PSMA Radioligand Therapy | ||
| NCT06449664 | Training for Men Undergoing Androgen Deprivation Therapy. | ||
| NCT00156884 | A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer | ||
| NCT02269982 | Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY | ||
| NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation | ||
| NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer | ||
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | ||
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | ||
| NCT02135484 | Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases | ||
| NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | ||
| NCT03440554 | Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization | ||
| NCT05918263 | Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial | ||
| NCT05702619 | Hypoxia-driven Prostate Cancer Genomics (HYPROGEN) | ||
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | ||
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial | ||
| NCT02856100 | Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer | ||
| NCT07050433 | Correlate Biomarkers for the SYNERGY- 201 Study | ||
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | ||
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | ||
| NCT05078151 | Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer |
